Compare DAIO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | MBRX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 23.5M |
| IPO Year | N/A | 2016 |
| Metric | DAIO | MBRX |
|---|---|---|
| Price | $3.06 | $4.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.22 | ★ $105.50 |
| AVG Volume (30 Days) | 26.6K | ★ 300.6K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,701,000.00 | N/A |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.88 | $4.75 |
| 52 Week High | $3.57 | $91.25 |
| Indicator | DAIO | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 58.29 |
| Support Level | $2.86 | $4.75 |
| Resistance Level | $3.20 | $7.98 |
| Average True Range (ATR) | 0.14 | 0.63 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 74.56 | 55.81 |
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.